-
1
-
-
0028890890
-
Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and Prt.
-
Bechtold, C. M., A. K. Patick, M. Alam, J. Greytok, J. A. Tino, P. Chen, E. Gordon, S. Ahmad, J. C. Barish, R. Zahler, P.-F. Lin, and R. Colonno. 1995. Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and Prt. Antimicrob. Agents Chemother. 39:374-379.
-
(1995)
Antimicrob. Agents Chemother.
, vol.39
, pp. 374-379
-
-
Bechtold, C.M.1
Patick, A.K.2
Alam, M.3
Greytok, J.4
Tino, J.A.5
Chen, P.6
Gordon, E.7
Ahmad, S.8
Barish, J.C.9
Zahler, R.10
Lin, P.-F.11
Colonno, R.12
-
2
-
-
0029891663
-
Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease
-
Bilello, J. A., P. A. Bilello, K. Stellrecht, J. Leonard, D. W. Norbeck, D. J. Kempf, T. Robins, and G. L. Drusano. 1996. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 40:1491-1497.
-
(1996)
Antimicrob. Agents Chemother.
, vol.40
, pp. 1491-1497
-
-
Bilello, J.A.1
Bilello, P.A.2
Stellrecht, K.3
Leonard, J.4
Norbeck, D.W.5
Kempf, D.J.6
Robins, T.7
Drusano, G.L.8
-
3
-
-
0031724008
-
Resistance to human immunodeficiency virus type 1 protease inhibitors
-
Boden, D., and M. Markowitz. 1998. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 42:2775-2783.
-
(1998)
Antimicrob. Agents Chemother.
, vol.42
, pp. 2775-2783
-
-
Boden, D.1
Markowitz, M.2
-
4
-
-
0029129495
-
SC-52151, a novel inhibitor of the human immunodeficiency virus protease
-
Bryant, M., D. Getman, M. Smidt, J. Marr, M. Clare, R. Dillard, D. Lansky, G. DeCrescenzo, R. Heintz, K. Houseman, K. Reed, J. Stolzenbach, J. Talley, M. Vazquez, and R. Mueller. 1995. SC-52151, a novel inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 39:2229-2234.
-
(1995)
Antimicrob. Agents Chemother.
, vol.39
, pp. 2229-2234
-
-
Bryant, M.1
Getman, D.2
Smidt, M.3
Marr, J.4
Clare, M.5
Dillard, R.6
Lansky, D.7
DeCrescenzo, G.8
Heintz, R.9
Houseman, K.10
Reed, K.11
Stolzenbach, J.12
Talley, J.13
Vazquez, M.14
Mueller, R.15
-
5
-
-
0032971472
-
Ritonavir and saquinavir combination therapy for the treatment of HIV infection
-
Cameron, D. W., A. J. Japour, Y. Xu, A. Hsu, J. Mellors, C. Farthing, C. Cohen, D. Poretz, M. Markowitz, S. Follansbee, J. B. Angel, D. McMahon, D. Ho, V. Devanarayan, R. Rode, M. Salgo, D. J. Kempf, R. Granneman, J. M. Leonard, and E. Sun. 1999. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13:213-224.
-
(1999)
AIDS
, vol.13
, pp. 213-224
-
-
Cameron, D.W.1
Japour, A.J.2
Xu, Y.3
Hsu, A.4
Mellors, J.5
Farthing, C.6
Cohen, C.7
Poretz, D.8
Markowitz, M.9
Follansbee, S.10
Angel, J.B.11
McMahon, D.12
Ho, D.13
Devanarayan, V.14
Rode, R.15
Salgo, M.16
Kempf, D.J.17
Granneman, R.18
Leonard, J.M.19
Sun, E.20
more..
-
6
-
-
0030671536
-
In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates
-
Chong, K.-T., and P. J. Pagano. 1997. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob. Agents Chemother. 41:2367-2373.
-
(1997)
Antimicrob. Agents Chemother.
, vol.41
, pp. 2367-2373
-
-
Chong, K.-T.1
Pagano, P.J.2
-
7
-
-
0021118703
-
Quantitative analysis of dose effect relationships: The combined effects of multiple drugs or enzyme inhibitors
-
Chou, T.-C, and P. Talalay. 1984. Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
-
(1984)
Adv. Enzyme Regul.
, vol.22
, pp. 27-55
-
-
Chou, T.-C.1
Talalay, P.2
-
8
-
-
10344263394
-
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
-
Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelski, D. J. Grahman, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodarkewitz, P. J. Deutsch, R. Y. Leavitt, F. E. Massari, J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
-
(1996)
J. Virol.
, vol.70
, pp. 8270-8276
-
-
Condra, J.H.1
Holder, D.J.2
Schleif, W.A.3
Blahy, O.M.4
Danovich, R.M.5
Gabryelski, L.J.6
Grahman, D.J.7
Laird, D.8
Quintero, J.C.9
Rhodes, A.10
Robbins, H.L.11
Roth, E.12
Shivaprakash, M.13
Yang, T.14
Chodarkewitz, J.A.15
Deutsch, P.J.16
Leavitt, R.Y.17
Massari, F.E.18
Mellors, J.W.19
Squires, K.E.20
Steigbigel, R.T.21
Teppler, H.22
Emini, E.A.23
more..
-
9
-
-
0030982931
-
1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity
-
Daluge, S. A., S. S. Good, M. B. Faletto, W. H. Miller, M. H. St. Clair, L. R. Boone, M. Tisdale, N. R. Parry, J. E. Reardon, R. E. Dornsife, D. R. Averett, and T. A. Krenitsky. 1997. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1082-1093.
-
(1997)
Antimicrob. Agents Chemother.
, vol.41
, pp. 1082-1093
-
-
Daluge, S.A.1
Good, S.S.2
Faletto, M.B.3
Miller, W.H.4
St. Clair, M.H.5
Boone, L.R.6
Tisdale, M.7
Parry, N.R.8
Reardon, J.E.9
Dornsife, R.E.10
Averett, D.R.11
Krenitsky, T.A.12
-
10
-
-
8944263470
-
Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication
-
Deminie, C., C. M. Bechtold, D. Stock, M. Alam, F. Djang, A. H. Balch, T.-C. Chou, M. Prichard, R. J. Colonno, and P.-F. Lin. 1996. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob. Agents Chemother. 40:1346-1351.
-
(1996)
Antimicrob. Agents Chemother.
, vol.40
, pp. 1346-1351
-
-
Deminie, C.1
Bechtold, C.M.2
Stock, D.3
Alam, M.4
Djang, F.5
Balch, A.H.6
Chou, T.-C.7
Prichard, M.8
Colonno, R.J.9
Lin, P.-F.10
-
11
-
-
0030903443
-
Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89
-
Faletto, M. B., W. H. Miller, E. P. Garvey, M. H. St. Clair, S. M. Daluge, and S. S. Good. 1997. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 41:1099-1107.
-
(1997)
Antimicrob. Agents Chemother.
, vol.41
, pp. 1099-1107
-
-
Faletto, M.B.1
Miller, W.H.2
Garvey, E.P.3
St. Clair, M.H.4
Daluge, S.M.5
Good, S.S.6
-
12
-
-
0032580479
-
HIV-protease inhibitors
-
Flexner, D. 1998. HIV-protease inhibitors. Drug Ther. 338:1281-1292.
-
(1998)
Drug Ther.
, vol.338
, pp. 1281-1292
-
-
Flexner, D.1
-
13
-
-
0030753305
-
Current antiretroviral therapy: An overview
-
Gulick, R. M. 1997. Current antiretroviral therapy: an overview. Quality Life Res. 6:471-474.
-
(1997)
Quality Life Res.
, vol.6
, pp. 471-474
-
-
Gulick, R.M.1
-
14
-
-
0442268112
-
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
-
Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, Jr., J. E. Feinberg, H. H. Balfour, Jr., L. R. Deyton, J. A. Chodakewitz, and M. A. Fischl. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725-733.
-
(1997)
N. Engl. J. Med.
, vol.337
, pp. 725-733
-
-
Hammer, S.M.1
Squires, K.E.2
Hughes, M.D.3
Grimes, J.M.4
Demeter, L.M.5
Currier, J.S.6
Eron J.J., Jr.7
Feinberg, J.E.8
Balfour H.H., Jr.9
Deyton, L.R.10
Chodakewitz, J.A.11
Fischl, M.A.12
-
15
-
-
0003415622
-
-
Kendall/Hunt Publishing Co., Dubuque, Iowa
-
Hubert, J. J. 1992. Bioassay. Kendall/Hunt Publishing Co., Dubuque, Iowa.
-
(1992)
Bioassay
-
-
Hubert, J.J.1
-
16
-
-
0026325601
-
Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S
-
Ido, E., H, Han, F. J. Kezdy, and J. Tang. 1991. Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S. J. Biol. Chem. 266:24359-24366.
-
(1991)
J. Biol. Chem.
, vol.266
, pp. 24359-24366
-
-
Ido, E.1
Han, H.2
Kezdy, F.J.3
Tang, J.4
-
17
-
-
0002051756
-
Infectivity assay (virus yield assay)
-
A. Aldovini and B. D. Walker (ed.). Stockton Press, New York, N.Y.
-
Johnson, V. A., and R. E. Byington. 1990. Infectivity assay (virus yield assay), p. 71-76. In A. Aldovini and B. D. Walker (ed.), Techniques in HIV research. Stockton Press, New York, N.Y.
-
(1990)
Techniques in HIV Research
, pp. 71-76
-
-
Johnson, V.A.1
Byington, R.E.2
-
18
-
-
0028231995
-
Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins
-
Kageyama, S., B. D. Anderson, B. L. Hoesterey, H. Hayashi, Y. Kiso, K. P. Flora, and H. Mitsuya. 1994. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob. Agents Chemother. 38:1107-1111.
-
(1994)
Antimicrob. Agents Chemother.
, vol.38
, pp. 1107-1111
-
-
Kageyama, S.1
Anderson, B.D.2
Hoesterey, B.L.3
Hayashi, H.4
Kiso, Y.5
Flora, K.P.6
Mitsuya, H.7
-
19
-
-
0029053608
-
Iterative protein structure-based drug design and synthesis of HIV protease inhibitors
-
Kalish, V., S. Kaldor, B. Shetty, J. Tatlock, J. Davies, M. Hammond, B. Dressman, J. Fritz, K. Appelt, S. Reich, L. Musick, B. Wu, and K. Su. 1995. Iterative protein structure-based drug design and synthesis of HIV protease inhibitors. Eur. J. Med. Chem. 30:202S-214S.
-
(1995)
Eur. J. Med. Chem.
, vol.30
-
-
Kalish, V.1
Kaldor, S.2
Shetty, B.3
Tatlock, J.4
Davies, J.5
Hammond, M.6
Dressman, B.7
Fritz, J.8
Appelt, K.9
Reich, S.10
Musick, L.11
Wu, B.12
Su, K.13
-
20
-
-
0028968902
-
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
-
Kempf, D. J., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, X.-P. Kong, N. E. Wideburg, A. Saldivar, L. Ruiz, W. M. Kati, H. L. Sham, T. Robins, K. D. Stewart, A. Hsu, J. J. Plattner, J. M. Leonard, and D. W. Norbeck. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl. Acad. Sci. USA 92:2484-2488.
-
(1995)
Proc Natl. Acad. Sci. USA
, vol.92
, pp. 2484-2488
-
-
Kempf, D.J.1
Marsh, K.C.2
Denissen, J.F.3
McDonald, E.4
Vasavanonda, S.5
Flentge, C.A.6
Green, B.E.7
Fino, L.8
Park, C.H.9
Kong, X.-P.10
Wideburg, N.E.11
Saldivar, A.12
Ruiz, L.13
Kati, W.M.14
Sham, H.L.15
Robins, T.16
Stewart, K.D.17
Hsu, A.18
Plattner, J.J.19
Leonard, J.M.20
Norbeck, D.W.21
more..
-
21
-
-
0031035968
-
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
-
Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
-
(1997)
Antimicrob. Agents Chemother.
, vol.41
, pp. 654-660
-
-
Kempf, D.J.1
Marsh, K.C.2
Kumar, G.3
Rodrigues, A.D.4
Denissen, J.F.5
McDonald, E.6
Kukulka, M.J.7
Hsu, A.8
Granneman, G.R.9
Baroldi, P.A.10
Sun, E.11
Pizzuti, D.12
Plattner, J.J.13
Norbeck, D.W.14
Leonard, J.M.15
-
22
-
-
0003806547
-
-
Prentice-Hall, Inc., Englewood Cliffs, N.J.
-
Keppel, G. 1982. Design and analysis: a researchers handbook, 2nd ed. Prentice-Hall, Inc., Englewood Cliffs, N.J.
-
(1982)
Design and Analysis: A Researchers Handbook, 2nd Ed.
-
-
Keppel, G.1
-
23
-
-
0026051925
-
Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles
-
Kohl, N. E., R. E. Diehl, E. Rands, L. J. Davis, M. G. Hanobik, B. Wolanski, and R. A. Dixon. 1991. Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles. J. Virol. 65:3007-3014.
-
(1991)
J. Virol.
, vol.65
, pp. 3007-3014
-
-
Kohl, N.E.1
Diehl, R.E.2
Rands, E.3
Davis, L.J.4
Hanobik, M.G.5
Wolanski, B.6
Dixon, R.A.7
-
24
-
-
0022546859
-
HTLV-III gag protein is processed in yeast cells by the virus pol-protease
-
Kramer, R. A., M. D. Schaber, A. M. Skalka, K. Ganguly, F. Wong-Staal, and E. P. Reddy. 1986. HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science 231:1580-1584.
-
(1986)
Science
, vol.231
, pp. 1580-1584
-
-
Kramer, R.A.1
Schaber, M.D.2
Skalka, A.M.3
Ganguly, K.4
Wong-Staal, F.5
Reddy, E.P.6
-
25
-
-
0031466883
-
HIV resistance to current therapies
-
Kuritzkes, D. R. 1997. HIV resistance to current therapies. Antiviral Ther. 2:61-67.
-
(1997)
Antiviral Ther.
, vol.2
, pp. 61-67
-
-
Kuritzkes, D.R.1
-
26
-
-
0027988547
-
Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy
-
Lin, P. F., H. Samanta, R. E. Rose, A. K. Patick, J. Trimble, C. M. Bechtold, D. R. Revie, C. K. Narayan, M. E. Federici, H. Li, A. Lee, R. E. Anderson, and R. J. Colonno. 1994. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J. Infect. Dis. 170:1157-1164.
-
(1994)
J. Infect. Dis.
, vol.170
, pp. 1157-1164
-
-
Lin, P.F.1
Samanta, H.2
Rose, R.E.3
Patick, A.K.4
Trimble, J.5
Bechtold, C.M.6
Revie, D.R.7
Narayan, C.K.8
Federici, M.E.9
Li, H.10
Lee, A.11
Anderson, R.E.12
Colonno, R.J.13
-
27
-
-
0028927329
-
Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: Relationship to drug resistance
-
Lin, Y., X. Lin, L. Hong, S. Foundling, R. L. Heinrikson, S. Thaisrivongs, W. Leelamanit, D. Raterman, M. Shah, B. M. Dunn, and J. Tang. 1995. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. Biochemistry 34:1143-1152.
-
(1995)
Biochemistry
, vol.34
, pp. 1143-1152
-
-
Lin, Y.1
Lin, X.2
Hong, L.3
Foundling, S.4
Heinrikson, R.L.5
Thaisrivongs, S.6
Leelamanit, W.7
Raterman, D.8
Shah, M.9
Dunn, B.M.10
Tang, J.11
-
28
-
-
0028877042
-
Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy
-
Livingston, D. J., S. Pazhanisamy, D. J. T. Porter, J. A. Partaledis, R. D. Tung, and G. R. Painter. 1998. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J. Infect. Dis. 172:1238-1245.
-
(1998)
J. Infect. Dis.
, vol.172
, pp. 1238-1245
-
-
Livingston, D.J.1
Pazhanisamy, S.2
Porter, D.J.T.3
Partaledis, J.A.4
Tung, R.D.5
Painter, G.R.6
-
29
-
-
0025099455
-
Novel fluorogenic substrates for assaying retroviral protease by resonance energy transfer
-
Matayoshi, E. D., G. T. Wang, G. A. Krafft, and J. Erickson. 1990. Novel fluorogenic substrates for assaying retroviral protease by resonance energy transfer. Science 247:954-958.
-
(1990)
Science
, vol.247
, pp. 954-958
-
-
Matayoshi, E.D.1
Wang, G.T.2
Krafft, G.A.3
Erickson, J.4
-
30
-
-
0032128592
-
Recent developments in HIV protease inhibitor therapy
-
Molla, A., G. R. Granneman, E. Sun, and D. J. Kempf. 1998. Recent developments in HIV protease inhibitor therapy. Antiviral Res. 39:1-23.
-
(1998)
Antiviral Res.
, vol.39
, pp. 1-23
-
-
Molla, A.1
Granneman, G.R.2
Sun, E.3
Kempf, D.J.4
-
32
-
-
0032899327
-
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infections
-
AIDS Clinical Trials Group 347 Study Team
-
Murphy, R. L., R. M. Gulick, V. DeGruttola, R. T. D'Aquila, J. J. Eron, J. P. Sommadossi, J. S. Currier, L. Smeaton, I. Frank, A. M. Caliendo, J. G. Gerber, R. Tung, and D. R. Kuritzkes. 1999. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infections. AIDS Clinical Trials Group 347 Study Team. J. Infect. Dis. 179:808-816.
-
(1999)
J. Infect. Dis.
, vol.179
, pp. 808-816
-
-
Murphy, R.L.1
Gulick, R.M.2
DeGruttola, V.3
D'Aquila, R.T.4
Eron, J.J.5
Sommadossi, J.P.6
Currier, J.S.7
Smeaton, L.8
Frank, I.9
Caliendo, A.M.10
Gerber, J.G.11
Tung, R.12
Kuritzkes, D.R.13
-
33
-
-
0030812875
-
Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro
-
Patick, A. K., T. J. Boritzki, and L. A. Bloom. 1997. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob. Agents Chemother. 41:2159-2164.
-
(1997)
Antimicrob. Agents Chemother.
, vol.41
, pp. 2159-2164
-
-
Patick, A.K.1
Boritzki, T.J.2
Bloom, L.A.3
-
35
-
-
0003007227
-
"Mini" reverse transcriptase (RT) assay
-
A. Aldovini and B. D. Walker (ed.), Stockton Press, New York, N.Y.
-
Potts, B. J. 1990. "Mini" reverse transcriptase (RT) assay, p. 103-106. In A. Aldovini and B. D. Walker (ed.), Techniques in HIV research, Stockton Press, New York, N.Y.
-
(1990)
Techniques in HIV Research
, pp. 103-106
-
-
Potts, B.J.1
-
37
-
-
0027416573
-
Strategic design and three-dimensional analysis of antiviral drug combinations
-
Prichard, M. N., L. E. Prichard, and C. Shipman, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545.
-
(1993)
Antimicrob. Agents Chemother.
, vol.37
, pp. 540-545
-
-
Prichard, M.N.1
Prichard, L.E.2
Shipman C., Jr.3
-
38
-
-
0025268321
-
Rational design of peptide-based HIV proteinase inhibitors
-
Roberts, N. A., J. A. Martin, D. Kinchington, A. V. Broadhurst, J. C. Craig, I. B. Duncan, S. A. Galpin, B. K. Handa, J. Kay, A. Krohn, R. W. Lambert, J. H. Merrett, J. S. Mills, K. E. B. Parkes, S. Redshaw, A. J. Ritchie, D. L. Taylor, G. J. Thomas, and P. J. Machin. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361.
-
(1990)
Science
, vol.248
, pp. 358-361
-
-
Roberts, N.A.1
Martin, J.A.2
Kinchington, D.3
Broadhurst, A.V.4
Craig, J.C.5
Duncan, I.B.6
Galpin, S.A.7
Handa, B.K.8
Kay, J.9
Krohn, A.10
Lambert, R.W.11
Merrett, J.H.12
Mills, J.S.13
Parkes, K.E.B.14
Redshaw, S.15
Ritchie, A.J.16
Taylor, D.L.17
Thomas, G.J.18
Machin, P.J.19
-
39
-
-
0029929255
-
In vitro activity of 141W94 (VX-478) in combination with other antiretroviral agents
-
St. Clair, M. H. S., J. Millard, J. Rooney, M. Tisdale, N. Parry, B. M. Sadler, M. R. Blum, and G. Painter. 1996. In vitro activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res. 29:53-56.
-
(1996)
Antiviral Res.
, vol.29
, pp. 53-56
-
-
St. Clair, M.H.S.1
Millard, J.2
Rooney, J.3
Tisdale, M.4
Parry, N.5
Sadler, B.M.6
Blum, M.R.7
Painter, G.8
-
40
-
-
0030849517
-
Clinically effective HIV-1 protease inhibitors
-
Vacca, J. P., and J. H. Condra. 1997. Clinically effective HIV-1 protease inhibitors. Drug Discov. Today 2:261-272.
-
(1997)
Drug Discov. Today
, vol.2
, pp. 261-272
-
-
Vacca, J.P.1
Condra, J.H.2
-
41
-
-
0028222149
-
L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor
-
Vacca, J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. Lin, I.-W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. R. Huff. 1994. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
-
(1994)
Proc. Natl. Acad. Sci. USA
, vol.91
, pp. 4096-4100
-
-
Vacca, J.P.1
Dorsey, B.D.2
Schleif, W.A.3
Levin, R.B.4
McDaniel, S.L.5
Darke, P.L.6
Zugay, J.7
Quintero, J.C.8
Blahy, O.M.9
Roth, E.10
Sardana, V.V.11
Schlabach, A.J.12
Graham, P.I.13
Condra, J.H.14
Gotlib, L.15
Holloway, M.K.16
Lin, J.17
Chen, I.-W.18
Vastag, K.19
Ostovic, D.20
Anderson, P.S.21
Emini, E.A.22
Huff, J.R.23
more..
-
42
-
-
0024578841
-
New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity
-
Weislow, O. S., R. Kiser, D. L. Fine, J. Bader, R. H. Shoemaker, and M. R. Boyd. 1989. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81:577-586.
-
(1989)
J. Natl. Cancer Inst.
, vol.81
, pp. 577-586
-
-
Weislow, O.S.1
Kiser, R.2
Fine, D.L.3
Bader, J.4
Shoemaker, R.H.5
Boyd, M.R.6
-
43
-
-
0028785708
-
L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase
-
Young, S. D., S. F. Britcher, L. O. Tran, L. S. Payne, W. C. Lumma, T. A. Lyle, J. R. Huff, P. S. Anderson, D. B. Olsen, S. S. Carroll, D. J. Pettibone, J. A. O'Brien, R. G. Ball, S. K. Balani, J. H. Lin, I.-W. Chen, W. A. Schleif, V. V. Sardana, W. J. Long, V. W. Byrnes, and E. A. Emini. 1995. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:2602-2605.
-
(1995)
Antimicrob. Agents Chemother.
, vol.39
, pp. 2602-2605
-
-
Young, S.D.1
Britcher, S.F.2
Tran, L.O.3
Payne, L.S.4
Lumma, W.C.5
Lyle, T.A.6
Huff, J.R.7
Anderson, P.S.8
Olsen, D.B.9
Carroll, S.S.10
Pettibone, D.J.11
O'Brien, J.A.12
Ball, R.G.13
Balani, S.K.14
Lin, J.H.15
Chen, I.-W.16
Schleif, W.A.17
Sardana, V.V.18
Long, W.J.19
Byrnes, V.W.20
Emini, E.A.21
more..
|